According to Needham, Boston Scientific has strong prospects around the world, even in areas where competitors are trying to capture market share. Analyst Mike Matson, who upgraded Boston Scientific for acquisition, said in a note to clients that a medical device manufactured by the company should still sell well despite new competition from Abbott Laboratories. The device, called a watchman, can be used to reduce the risk of stroke in patients with irregular heartbeats. “BSX is currently reporting quarterly WATCHMAN sales. Although management has stated that this is due to a reorganization of its reporting segments rather than a bullish sign, we cannot believe it. that they would choose to do this if they wrote Matson. And even if Abbott’s product gains market share, Boston Scientific will be able to offset that with strength elsewhere, according to Needham. currently analyze the sensitivity of BSX’s overall revenue growth to WATCHMAN’s growth and we now believe 1) BSX can sustain single-digit organic growth even assuming a high WATCHMAN’s growth slowed moderately; and 2) BSX will be able to gain at least a part of Matson wrote: “Also, Needham says Boston Scientific could be a takeover target if mergers and acquisitions activity in the healthcare sector increases High, which has the potential to be profitable for shareholders.Needham has set a price target of $48 per share for Boston Scientific, which is nearly 20% higher than the stock closed Thursday. Michael Bloom of CNBC contributed to this report.